Tinted Daily SPF-30 Moisturizer, DFM30, Reduces Redness and Improves Rosacea-Prone Skin - Dermatology Advisor

Posted: 11 Apr 2019 12:00 AM PDT

A study found that DFM30, a tinted daily SPF-30 facial moisturizer, was associated with improvements in cutaneous barrier function and reduction in skin dryness and redness in rosacea-prone skin. Findings from the study were published in the Journal of Cosmetic Dermatology.

In the first of a series of 2 studies, researchers measured electrical capacitance and transepidermal water loss at baseline, 2, 4, 8, and 24 hours after a single DFM30 application, as well as on a control site in healthy women with dry skin (n=21). The second study enrolled women with mild to moderate rosacea and nontransient erythema (n=33), and tested the efficacy and tolerability after once-daily DFM30. Efficacy and tolerability outcomes were assessed with a chromameter, photograph analysis, and trained rater and patient evaluations to the 22nd day of application.

Compared with baseline, there were significant increases in electrical capacitance at 2 hours (29.8 ± 6.5 vs 36.2 ± 6.5, respectively; P <.001), 4 hours (29.8 ± 6.5 vs 33.8 ± 5.9, respectively; P <.001), and 8 hours (29.8 ± 6.5 vs 32.7 ± 5.3, respectively; P =.002) after application in the first study. The researchers also observed significant decreases in transepidermal water loss at 2 hours (7.3 ± 1.3 vs 6.3 ± 1.4; P =.03), 4 hours (7.3 ± 1.3 vs 6.6 ± 1.4; P =.001), 8 hours (7.3 ± 1.3 vs 6.9 ± 1.4; P =.042), and 24 hours (7.3 ± 1.3 vs 6.5 ± 1.3; P =.003) after applying DFM30 to healthy women.

In the second study, up to 33.3% of participants experienced improved coverage of skin redness with DFM30 on day 1 compared with baseline (P =.002). Fewer reports of redness were made on day 8 vs day 3 (P =.016). Skin dryness and tightness/tension were reportedly lower approximately 30 minutes after the first DFM30 application. According to image analysis, skin redness was noticeably lower on day 22 vs baseline on the unaffected forehead. The entire cohort stated they would purchase DFM30 because of its ability to both relieve as well as neutralize visible redness.

Limitations of the study were the inclusion of a predominantly female cohort and the small sample size, as well as the lack of a randomized placebo-controlled design.

The researchers concluded that their study demonstrates "that DFM30 is an effective and well-tolerated moisturizer that improves cutaneous barrier function and the visible appearance of rosacea-prone skin."

Follow @DermAdvisor

Reference

Baldwin H, Santoro F, Lachmann N, Teissedre S. A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin [published online February 25, 2019]. J Cosmet Dermatol. doi: 10.1111/jocd.12889.

Topics:

Rosacea

Severe Acute Respiratory Syndrome